Bioline RX Gets European Device Confirmation for Bl-5010 Drug
This article is for subscribers only.
Bioline RX Ltd. said it received European confirmation for the classification of its BL-5010 drug to treat seborrheic keratosis skin lesions, as a medical device Class IIa, according to a statement filed today with the Tel Aviv Stock Exchange.